SIRIUS is the "serious" response to the prevalence of liver cirrhosis in Slovakia. We plan to screen adult Slovaks without acute or life-threatening comorbidity and without known liver disease (except from non-alcoholic fatty liver disease) for liver fibrosis by transient elastography (in community) or FIB-4 score (in outpatient clinics).
According to the Lancet Gastroenterology and Hepatology, Slovakia ranks at the top of the prevalence of liver cirrhosis in the world. Moreover, liver diseases are the leading cause of death in the age-group of 25 - 50 years-old. SIRIUS is the response conceived by the governing board of the Slovak society of hepatology with two main aims: to screen for liver fibrosis and to spread the largely unknown information in community, and primary-care sector.
Study Type
OBSERVATIONAL
Enrollment
1,000
Both tests belong to the group of non-invasive tests for liver fibrosis (transient elastography belongs to the imaging-based tests and FIB-4 to the blood-based tests)
F.D.Roosevelt Teaching Hospital
Banská Bystrica, Slovakia
University Hospital Bratislava
Bratislava, Slovakia
Pasteur University Hospital
Košice, Slovakia
Liver fibrosis
The amount of fibrous tissue in the liver according to non-invasive tests
Time frame: August, 2022 - to September 2023
Non-alcoholic fatty liver disease
The amount of fat in the liver parenchyma by the non-invasive tests CAP and FLI
Time frame: August, 2022 - September, 2023
Alcohol associated liver disease
Liver disease plus AUDIT score testimonyijng to the harmful alcohol use
Time frame: August, 2022 - September, 2023
Body mass index
As calculated from height and weight (together with waist-to-hip ratio)
Time frame: August, 2022 - September, 2023
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.